Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2025)

Anaptysbio (ANAB) has disclosed Change in Accured Expenses for 10 consecutive years, with -$22.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 44.04% year-over-year to -$22.4 million, compared with a TTM value of -$87.3 million through Dec 2025, down 158.08%, and an annual FY2025 reading of -$87.3 million, down 158.08% over the prior year.
  • Change in Accured Expenses was -$22.4 million for Q4 2025 at Anaptysbio, down from -$18.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.5 million in Q1 2023 and bottomed at -$40.0 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is -$5.3 million, with a median of -$844500.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses soared 8706.67% in 2023, then crashed 2573.36% in 2024.
  • Year by year, Change in Accured Expenses stood at -$5.3 million in 2021, then skyrocketed by 190.81% to $4.8 million in 2022, then crashed by 131.0% to -$1.5 million in 2023, then plummeted by 2573.36% to -$40.0 million in 2024, then soared by 44.04% to -$22.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ANAB at -$22.4 million in Q4 2025, -$18.6 million in Q3 2025, and -$22.3 million in Q2 2025.